GeneDx Holdings Corp. Files 8-K on Financials

Ticker: WGSWW · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1818331

Genedx Holdings Corp. 8-K Filing Summary
FieldDetail
CompanyGenedx Holdings Corp. (WGSWW)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $379.50
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K, company-update

TL;DR

GeneDx Holdings Corp. filed an 8-K on Jan 13, 2025, detailing financial results and operations.

AI Summary

GeneDx Holdings Corp. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company was formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc.

Why It Matters

This 8-K filing provides crucial updates on GeneDx Holdings Corp.'s financial performance and operational status, which is important for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial disclosure filing and does not inherently present new risks.

Key Players & Entities

  • GeneDx Holdings Corp. (company) — Registrant
  • Sema4 Holdings Corp. (company) — Former Company Name
  • CM Life Sciences, Inc. (company) — Former Company Name
  • January 13, 2025 (date) — Date of Report

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on GeneDx Holdings Corp.'s Results of Operations and Financial Condition, as well as provide Regulation FD Disclosures and Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on January 13, 2025.

What were GeneDx Holdings Corp.'s previous names?

GeneDx Holdings Corp. was formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc.

In which state is GeneDx Holdings Corp. incorporated?

GeneDx Holdings Corp. is incorporated in Delaware.

What is the business address of GeneDx Holdings Corp.?

The business address of GeneDx Holdings Corp. is 333 Ludlow Street, North Tower, 8th Floor, Stamford, CT 06902.

Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-13 08:36:45

Key Financial Figures

  • $0.0001 — stered Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market L
  • $379.50 — mon stock, each at an exercise price of $379.50 per share WGSWW The Nasdaq Stock Market

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. The information set forth in Item 7.01 below is incorporated by reference into this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, GeneDx Holdings Corp. (the "Company") issued a press release (the "Press Release") announcing the Company's expectations regarding its preliminary, unaudited revenue for the fourth quarter and the year ended 2024, exome and genome test result volumes for the fourth quarter and cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024. A copy of the Press Release is included with this Form 8-K for convenience and attached hereto as Exhibit 99.1. Also on January 13, 2024, the Company is furnishing as Exhibit 99.2 hereto a copy of the investor presentation to be used at the 43rd Annual J.P. Morgan Healthcare Conference event. The information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No Description 99.1 Press Release, dated January 13, 2025, regarding Preliminary 2024 Financial Results 99.2 Investor Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEDX HOLDINGS CORP. Date: January 13, 2025 By: /s/ Katherine Stueland Name: Katherine Stueland Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.